Portal de Periódicos da CAPES

mRNA and microRNA Expression Profiles of the NCI-60 Integrated with Drug Activities

2010; American Association for Cancer Research; Volume: 9; Issue: 5 Linguagem: Inglês

10.1158/1535-7163.mct-09-0965

1538-8514

Hongfang Liu, Petula D'Andrade, Stephanie Fulmer-Smentek, Philip L. Lorenzi, Kurt W. Kohn, John N. Weinstein, Yves Pommier, William C. Reinhold,

RNA Interference and Gene Delivery

Abstract As part of the Spotlight on Molecular Profiling series, we present here new profiling studies of mRNA and microRNA expression for the 60 cell lines of the National Cancer Institute (NCI) Developmental Therapeutics program (DTP) drug screen (NCI-60) using the 41,000-probe Agilent Whole Human Genome Oligo Microarray and the 15,000-feature Agilent Human microRNA Microarray V2. The expression levels of ∼21,000 genes and 723 human microRNAs were measured. These profiling studies include quadruplicate technical replicates for six and eight cell lines for mRNA and microRNA, respectively, and duplicates for the remaining cell lines. The resulting data sets are freely available and searchable online in our CellMiner database. The result indicates high reproducibility for both platforms and an essential biological similarity across the various cell types. The mRNA and microRNA expression levels were integrated with our previously published 1,429-compound database of anticancer activity obtained from the NCI DTP drug screen. Large blocks of both mRNAs and microRNAs were identified with predominately unidirectional correlations to ∼1,300 drugs, including 121 drugs with known mechanisms of action. The data sets presented here will facilitate the identification of groups of mRNAs, microRNAs, and drugs that potentially affect and interact with one another. Mol Cancer Ther; 9(5); 1080–91. ©2010 AACR.